A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Public ClinicalTrials.gov record NCT05365581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Study identification
- NCT ID
- NCT05365581
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Enrollment
- 398 participants
Conditions and interventions
Conditions
Interventions
- ASP2138 Drug
- Capecitabine Drug
- Fluorouracil Drug
- Irinotecan Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Paclitaxel Drug
- Pembrolizumab Drug
- Ramucirumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 6, 2022
- Primary completion
- May 30, 2028
- Completion
- May 30, 2028
- Last update posted
- May 4, 2026
2022 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine Medical Center | Orange | California | 92868 | Recruiting |
| UCLA Dept of Medicine - Hematology/Oncology, Santa Monica | Santa Monica | California | 90404 | Withdrawn |
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | Completed |
| NYU Langone Medical Center - NYU Medical Oncology Associates | New York | New York | 10016 | Recruiting |
| Columbia University | New York | New York | 10032 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Duke Children's Hospital and Health Center | Durham | North Carolina | 27710 | Recruiting |
| Wake Forest University Baptist Health | Winston-Salem | North Carolina | 27103 | Recruiting |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | Recruiting |
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05365581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05365581 live on ClinicalTrials.gov.